Alliance/CALGB 80802 impact of hepatitis C (HCV) on doxorubicin (D) + sorafenib (S) vs. s in patients (pts) advanced HCC (aHCC)
- Citation:
- J Clin Oncol vol 39 (3_suppl) 325
- Meeting Instance:
- ASCO GI 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3764
- Pharmas:
- Bayer
- Grants:
- U10CA180821, U10CA180882, U24CA196171;
- Corr. Author:
- Authors:
- Imane El Dika Susan M. Geyer Andrew Nixon Federico Innocenti Qian Shi Sawyer B. Jacobson Amin Yaqubie Juan Lopez Binhui Huang Yi-Wei Tang Yujia Wen Lawrence H. Schwartz Monica M. Bertagnolli Jeffrey Meyerhardt Eileen M. O'Reilly Alan P. Venook Ghassan K. Abou-Alfa
- Networks:
- CA136, LAPS-MA036, LAPS-NC007, LAPS-NC010, LAPS-NY016
- Study
- CALGB-80802
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: